LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-20
Case ID: NM_002528.7_c.332A_G_20261120_231829
Framework: ACMG/AMP 2015
Variant classification summary

NM_002528.7:c.332A>G

NTHL1  · NP_002519.2:p.(Tyr111Cys)  · NM_002528.7
GRCh37: chr16:2096151 T>C  ·  GRCh38: chr16:2046150 T>C
Gene: NTHL1 Transcript: NM_002528.7
Final call
VUS
PM2 moderate BP1 supporting
All criteria require review: For research and educational purposes only.
Gene
NTHL1
Transcript
NM_002528.7
Protein
NP_002519.2:p.(Tyr111Cys)
gnomAD AF
2.1701200510412237e-05 (v4.1)
ClinVar
Uncertain significance
OncoKB
Interpretation summary
Generated evidence synthesis
1
PM2 moderate: the variant is extremely rare in gnomAD and no homozygotes are observed.
2
BP1 supporting: NTHL1 disease is primarily associated with biallelic loss-of-function variants rather than missense variants.
Final determination: Under generic ACMG/AMP 2015 rules, one moderate pathogenic criterion plus one supporting benign criterion meets neither a pathogenic nor a benign combination threshold, so the call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
PS1 Not met Not met: ClinVar records p.Tyr111Cys as uncertain significance, with no established pathogenic same-amino-acid substitution identified.
clinvar
PS2 Not assessed Not assessed: no documented affected proband with confirmed maternity and paternity, parental genotypes, and absent family history is available for this variant.
PMID:33980861
PS3 Not assessed Not assessed: no variant-specific functional assay or damaging-effect readout is reported for NTHL1 p.(Tyr111Cys), so PS3 Strong cannot be applied.
PMID:33980861 PMID:26467025
PS4 Not met Not met: the available case-control study found aggregate NTHL1 missense enrichment, but no c.332A>G carrier counts, OR, or 95% CI were reported.
PMID:33980861 PMID:25394175 PMID:32239880
PM1 Not assessed Not assessed: an Endonuclease III domain is reported, but residue boundaries and the required absence of benign variation at Tyr111 are not established.
PMID:33980861 hotspots
PM2 Met Met at Moderate: gnomAD v4.1 AF is 2.17012e-05 with zero homozygotes, below the 0.0001 PM2 cutoff for extremely low frequency.
gnomad_v2 gnomad_v4
PM3 Not assessed Not assessed: no report documents a pathogenic NTHL1 variant in trans with c.332A>G or provides parental/offspring phase testing.
PMID:33980861
PM4 N/A Not applicable: PM4 requires a protein-length change, and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
PM5 Not met Not met: no different pathogenic missense change at Tyr111 was identified, and the exact variant itself is classified as uncertain significance.
clinvar
PM6 Not assessed Not assessed: no affected-proband report documents this variant as assumed de novo without confirmed maternity and paternity testing.
PMID:33980861
PP1 Not assessed Not assessed: no affected relatives, genotype results, or informative meioses demonstrate co-segregation of this variant with disease.
PMID:33980861
PP2 Not met Not met: NTHL1 disease is established primarily through biallelic loss of function, while heterozygous missense effects are described as modest or low penetrance.
PMID:33980861
PP3 Not met Not met: missense REVEL is 0.409, below the PP3 supporting threshold of >= 0.644.
revel
PP4 Not assessed Not assessed: no patient phenotype, family history, or disease-specific clinical diagnosis is provided for evaluating PP4.
PP5 Not met Not met: ClinVar has zero expert-panel classifications for this exact variant, and all six laboratory submissions report Uncertain significance.
clinvar PMID:25741868 PMID:33980861 PMID:25394175 PMID:32239880
BA1 Not met Not met: grpmax FAF is 2.863e-05 in gnomAD v2.1 and 1.567e-05 in v4.1, both far below the 0.05 BA1 threshold.
gnomad_v2 gnomad_v4 clinvar
BS1 Not met Not met: the highest qualifying grpmax FAF is 2.863e-05, far below the generic 0.01 BS1 threshold.
gnomad_v2 gnomad_v4
BS2 Not assessed Not assessed: gnomAD reports zero homozygotes but provides no individual healthy-adult phenotype or age information required for BS2.
gnomad_v2 gnomad_v4
BS3 Not assessed Not assessed: no variant-specific functional assay demonstrates preserved NTHL1 protein function or splicing, so BS3 Strong cannot be applied.
PMID:33980861 PMID:26467025
BS4 Not assessed Not assessed: no affected relatives are documented as negative for this variant, and no pedigree data permit evaluation of non-segregation.
PMID:33980861
BP1 Met Met, supporting: established NTHL1 tumor syndrome is caused by biallelic loss-of-function variants, while missense effects are modest and low penetrance.
PMID:33980861
BP2 Not assessed Not assessed: no report documents c.332A>G in trans or cis with a pathogenic variant, and no phase data are available.
PMID:33980861
BP3 N/A Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
BP4 Not met Not met: missense REVEL is 0.409, above the BP4 supporting threshold of <= 0.29.
revel
BP5 Not assessed Not assessed: no documented case links this exact variant with an alternate molecular basis for the disease.
BP6 Not met Not met: no exact-variant ClinVar expert-panel Benign/Likely benign classification exists, while all six laboratory submissions are Uncertain significance.
clinvar PMID:25394175 PMID:32239880
BP7 N/A Not applicable: BP7 requires a synonymous variant, and this is a missense variant.
generic_acmg_combination_rules
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.